Clinical trial: the effects of a trans‐galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome

D. Silk,A. Davis,J. Vulevic,G. Tzortzis,G. Gibson
DOI: https://doi.org/10.1111/j.1365-2036.2008.03911.x
2009-03-01
Abstract:Background  Gut microflora‐mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS).
What problem does this paper attempt to address?